CG Oncology (CGON) closed at $78.94 on November 17, 2026, down 6.9% from the previous close, on volume of 3,062,194 shares (30-day average 1,363,210).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Call with Delta Hedge | 20-Nov-26 75 C +250,000 Stock | 6,250 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), CG Oncology, Inc. (CGON)
TipRanks (Mon, 16-Nov 12:32 PM ET)
Analysts’ Top Healthcare Picks: CG Oncology, Inc. (CGON), Tyra Bioscience (TYRA)
TipRanks (Mon, 16-Nov 11:50 AM ET)
CG Oncology rises on phase 3 data for bladder cancer immunotherapy
Seeking Alpha News (Mon, 16-Nov 11:27 AM ET)
CG Oncology Reports Positive Phase 3 Bladder Cancer Trial Results
TipRanks (Mon, 16-Nov 8:51 AM ET)
Globe Newswire (Mon, 16-Nov 8:00 AM ET)
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Fri, 6-Nov 8:15 AM ET)
Globe Newswire (Tue, 13-Oct 8:00 AM ET)
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
PRNewswire (Mon, 12-Oct 9:32 PM ET)
CG Oncology to Present at Upcoming Investor Conferences in September
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
CG Oncology Bolsters Cash Position to $1.1 Billion While Advancing Multiple Clinical Milestones
Market Chameleon (Fri, 8-May 5:24 AM ET)
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
CG Oncology trades on the NASDAQ stock market under the symbol CGON.
As of November 17, 2026, CGON stock price declined to $78.94 with 3,062,194 million shares trading.
CGON has a beta of 0.33, meaning it tends to be less sensitive to market movements. CGON has a correlation of 0.01 to the broad based SPY ETF.
CGON has a market cap of $7.05 billion. This is considered a Mid Cap stock.
Last quarter CG Oncology reported $2 million in Revenue and -$.64 earnings per share. This beat revenue expectation by $960,416 and exceeded earnings estimates by $.18.
The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, IWM, XBI, VB, VBK.
CGON has outperformed the market in the last year with a price return of +92.5% while the SPY ETF gained +10.1%. CGON has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.2% and +27.4%, respectively, while the SPY returned -5.4% and -2.6%, respectively.
CGON support price is $81.81 and resistance is $87.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.